NASDAQ:CDLXCardlytics Stock Price, Forecast & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.36. The business earned $28.22 million during the quarter, compared to the consensus estimate of $30.84 million. Cardlytics had a negative return on equity of 26.42% and a negative net margin of 18.86%. The company's quarterly revenue was down 42.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.12) EPS.
View Cardlytics' earnings history.

6 analysts have issued twelve-month target prices for Cardlytics' shares. Their forecasts range from $26.00 to $75.00. On average, they anticipate Cardlytics' share price to reach $55.17 in the next twelve months.
View analysts' price targets for Cardlytics.

Media headlines about CDLX stock have been trending neutral on Tuesday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cardlytics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Cardlytics.

Cardlytics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 2,770,000 shares, a decrease of 19.5% from the January 15th total of 3,440,000 shares. Based on an average daily trading volume, of 559,900 shares, the short-interest ratio is currently 4.9 days.
View Cardlytics' Short Interest.

Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), DouYu International (DOYU), Medallia (MDLA), Switch (SWCH), Pluralsight (PS), Tripadvisor (TRIP), SVMK (SVMK), 21Vianet Group (VNET), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN), Health Catalyst (HCAT), Eventbrite (EB) and the Rubicon Project (MGNI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Trade Desk (TTD), Caterpillar (CAT), Walt Disney (DIS), Docusign (DOCU), Advanced Micro Devices (AMD), Roku (ROKU), Square (SQ) and Twilio (TWLO).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a number of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Victory Capital Management Inc. (1.16%), Great Lakes Advisors LLC (0.72%), Ziegler Capital Management LLC (0.34%) and New York State Common Retirement Fund (0.30%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Frontier Capital Management Co. LLC, Hancock Whitney Corp, Hussman Strategic Advisors Inc., Jennison Associates LLC, and Brave Asset Management Inc.. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics.

CDLX stock was bought by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, First Trust Advisors LP, Serengeti Asset Management LP, Tygh Capital Management Inc., Ziegler Capital Management LLC, Roubaix Capital LLC, Victory Capital Management Inc., and Calamos Advisors LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

Cardlytics has a market capitalization of $0.00 and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]